Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model |
| |
Authors: | Melissa A Barber Tong Zhang Bethany A Gagne Jo A Van Ginderachter Patrick De Baetselier Charles L Sentman |
| |
Institution: | (1) Department of Microbiology and Immunology, Dartmouth Medical School, 6W Borwell Bldg, One Medical Center Dr, Lebanon, NH 03756, USA;(2) Lab of Cellular and Molecular Immunology, Department of Molecular and Cellular Interactions, VIB, Brussels, Belgium;(3) Lab of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium |
| |
Abstract: | Background NK cell activity is regulated in part by inhibitory receptors that bind to MHC class I molecules. It is possible to enhance
NK cell cytotoxicity against tumor cells by preventing the interaction of these inhibitory receptors with their MHC class
I ligands.
Results In this study, we determined that Ly49G2 is an inhibitory receptor in AKR mice for self-MHC class I, and AKR Ly49G2 has an
identical sequence to BALB/c Ly49G2. Blockade of Ly49G2 receptors in vivo resulted in decreased growth of BW-Sp3 lymphoma
cells when the tumor cells were given i.v. but not when the tumor cells were inoculated into the flank forming a solid tumor.
However, NK cells were involved in inhibiting the growth of BW-Sp3 tumor cells in the flank.
Conclusion These data demonstrate that the effectiveness of inhibitory receptor blockade depends upon the tissue location of the tumor
cells. |
| |
Keywords: | Natural Killer Cells Tumor Immunity Immunotherapy AKR Lymphoma |
本文献已被 PubMed SpringerLink 等数据库收录! |
|